FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893221505> ?p ?o ?g. }

• W2893221505 abstract "Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed them in ODYSSEY-KT through the pre-specified Korean subanalysis.In the ODYSSEY-KT study, South Korean and Taiwanese patients with hypercholesterolemia and high cardiovascular risks were randomized (1:1) to alirocumab or placebo. Alirocumab was self-administered subcutaneously at 75 mg every 2 weeks with a maximally tolerated statin dose with or without other lipid-modifying therapies. Alirocumab dose was increased to 150 mg every 2 weeks at week 12 if low density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL at week 8. Primary endpoint was percent change in LDL-C from baseline to week 24. Results from Korean cohort (n = 83: 40 for alirocumab and 43 for placebo, respectively) analyses are reported here.In alirocumab group, the least square of mean change percent in LDL-C levels was -65.7% (placebo: 11.1%; p < 0.0001) and 92.0% of them achieved LDL-C < 70 mg/dL (placebo: 12.7%; p < 0.0001) at week 24. Alirocumab also showed significantly greater improvements in high density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol, lipoprotein(a), and apolipoprotein B than placebo (p < 0.05). Two consecutive calculated LDL-C values < 25 mg/dL were observed in 37.5% of alirocumab-treated patients. Overall, 45.0% alirocumab-treated and 51.2% placebo-treated patients experienced treatment-emergent adverse events (TEAEs) without discontinuation of treatment due to TEAEs.Alirocumab has demonstrated to be effective in improvement of LDL-C and related lipid profiles in Korean cohort. Alirocumab was generally well tolerated with no significant safety signals." @default.
• W2893221505 created "2018-10-05" @default.
• W2893221505 creator A5020677944 @default.
• W2893221505 creator A5025154210 @default.
• W2893221505 creator A5040795581 @default.
• W2893221505 creator A5080295782 @default.
• W2893221505 creator A5087463011 @default.
• W2893221505 creator A5091510154 @default.
• W2893221505 creator A5091705050 @default.
• W2893221505 date "2019-11-01" @default.
• W2893221505 modified "2023-10-17" @default.
• W2893221505 title "Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study" @default.
• W2893221505 cites W1423581981 @default.
• W2893221505 cites W1962272706 @default.
• W2893221505 cites W1985747185 @default.
• W2893221505 cites W2001328643 @default.
• W2893221505 cites W2045812147 @default.
• W2893221505 cites W2064422331 @default.
• W2893221505 cites W2105342657 @default.
• W2893221505 cites W2121568629 @default.
• W2893221505 cites W2133247967 @default.
• W2893221505 cites W2139575534 @default.
• W2893221505 cites W2141898196 @default.
• W2893221505 cites W2166934777 @default.
• W2893221505 cites W2218353190 @default.
• W2893221505 cites W2319057797 @default.
• W2893221505 cites W2333109535 @default.
• W2893221505 cites W2337214440 @default.
• W2893221505 cites W2483885489 @default.
• W2893221505 cites W2509676484 @default.
• W2893221505 cites W2546044729 @default.
• W2893221505 cites W2590152204 @default.
• W2893221505 cites W2596179513 @default.
• W2893221505 cites W2600376829 @default.
• W2893221505 cites W2604674371 @default.
• W2893221505 cites W2765581909 @default.
• W2893221505 cites W2802888268 @default.
• W2893221505 doi "https://doi.org/10.3904/kjim.2018.133" @default.
• W2893221505 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6823573" @default.
• W2893221505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30257549" @default.
• W2893221505 hasPublicationYear "2019" @default.
• W2893221505 type Work @default.
• W2893221505 sameAs 2893221505 @default.
• W2893221505 citedByCount "4" @default.
• W2893221505 countsByYear W28932215052019 @default.
• W2893221505 countsByYear W28932215052020 @default.
• W2893221505 crossrefType "journal-article" @default.
• W2893221505 hasAuthorship W2893221505A5020677944 @default.
• W2893221505 hasAuthorship W2893221505A5025154210 @default.
• W2893221505 hasAuthorship W2893221505A5040795581 @default.
• W2893221505 hasAuthorship W2893221505A5080295782 @default.
• W2893221505 hasAuthorship W2893221505A5087463011 @default.
• W2893221505 hasAuthorship W2893221505A5091510154 @default.
• W2893221505 hasAuthorship W2893221505A5091705050 @default.
• W2893221505 hasBestOaLocation W28932215051 @default.
• W2893221505 hasConcept C126322002 @default.
• W2893221505 hasConcept C134018914 @default.
• W2893221505 hasConcept C142724271 @default.
• W2893221505 hasConcept C197934379 @default.
• W2893221505 hasConcept C204787440 @default.
• W2893221505 hasConcept C27081682 @default.
• W2893221505 hasConcept C2776839432 @default.
• W2893221505 hasConcept C2778114629 @default.
• W2893221505 hasConcept C2778163477 @default.
• W2893221505 hasConcept C2780072125 @default.
• W2893221505 hasConcept C2780745583 @default.
• W2893221505 hasConcept C2780902209 @default.
• W2893221505 hasConcept C2780948078 @default.
• W2893221505 hasConcept C2908647359 @default.
• W2893221505 hasConcept C43554185 @default.
• W2893221505 hasConcept C62746215 @default.
• W2893221505 hasConcept C71924100 @default.
• W2893221505 hasConcept C90924648 @default.
• W2893221505 hasConcept C99454951 @default.
• W2893221505 hasConceptScore W2893221505C126322002 @default.
• W2893221505 hasConceptScore W2893221505C134018914 @default.
• W2893221505 hasConceptScore W2893221505C142724271 @default.
• W2893221505 hasConceptScore W2893221505C197934379 @default.
• W2893221505 hasConceptScore W2893221505C204787440 @default.
• W2893221505 hasConceptScore W2893221505C27081682 @default.
• W2893221505 hasConceptScore W2893221505C2776839432 @default.
• W2893221505 hasConceptScore W2893221505C2778114629 @default.
• W2893221505 hasConceptScore W2893221505C2778163477 @default.
• W2893221505 hasConceptScore W2893221505C2780072125 @default.
• W2893221505 hasConceptScore W2893221505C2780745583 @default.
• W2893221505 hasConceptScore W2893221505C2780902209 @default.
• W2893221505 hasConceptScore W2893221505C2780948078 @default.
• W2893221505 hasConceptScore W2893221505C2908647359 @default.
• W2893221505 hasConceptScore W2893221505C43554185 @default.
• W2893221505 hasConceptScore W2893221505C62746215 @default.
• W2893221505 hasConceptScore W2893221505C71924100 @default.
• W2893221505 hasConceptScore W2893221505C90924648 @default.
• W2893221505 hasConceptScore W2893221505C99454951 @default.
• W2893221505 hasLocation W28932215051 @default.
• W2893221505 hasLocation W28932215052 @default.
• W2893221505 hasLocation W28932215053 @default.
• W2893221505 hasLocation W28932215054 @default.
• W2893221505 hasOpenAccess W2893221505 @default.
• W2893221505 hasPrimaryLocation W28932215051 @default.
• W2893221505 hasRelatedWork W1594296636 @default.

• next